Editorial Board
John Allan
New York Presbyterian Hospital-Weill Cornell Medical Center · United States
Editorial leadership for Journal of Hematology and Oncology Research ISSN 2372-6601
Research interests
- Plasma Cell Dyscrasias Leukemia Stem Cell Biology Coagulation
Biography
Honors, and Memberships
- Alpha Omega Alpha
- Arnold P. Gold Humanism in Medicine Honor Society
- Alpha Sigma Nu Jesuit Honor Society
- American Society of Clinical Oncology
- American Society of Hematology
Selected publications
- Outcomes of COVID-19 in patients with CLL: a multicenter international experience 2020 cited 278×
- Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort 2022 cited 228×
- Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy 2020 cited 106×
- ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models 2021 cited 86×
- Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice 2019 cited 82×
- COVID-19 in patients with CLL: improved survival outcomes and update on management strategies 2021 cited 62×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JHOR for your work?
This journal is guided by John Allan (New York Presbyterian Hospital-Weill Cornell Medical Center) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.